Valeant to Sell $1.75B in Stock to Fund Bausch + Lomb Acquisition

Valeant Pharmaceuticals, based in Laval, Quebec, has announced plans to sell $1.75 billion in stock to support its acquisition of Bausch + Lomb, according to a PharmaLive report.

Valeant will pay $4.5 billion to acquire Bausch + Lomb and another $4.2 billion to cover the ophthalmic product company's debt.

Valeant did not disclose the number of shares it plans to sell.

More Articles on Ophthalmology:
EyeCRO, Calvert Labs Partner to Perform Preclinical Studies of Ophthalmic Drugs
ForSight VISION5 Names John Maroney President, CEO
16 Statistics on Ophthalmologist Burnout




Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast